Welcome to our dedicated page for Absci Corporation news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci Corporation stock.
Absci Corporation (Nasdaq: ABSI) is a leading company that leverages the power of artificial intelligence to drive the next generation of drug discovery and development. Based in Vancouver, WA, Absci combines advanced AI technology with scalable wet lab processes, aiming to revolutionize the speed and efficacy of creating novel biologics.
Absci's core business revolves around its Integrated Drug Creation™ platform, which offers a unified approach to biologic drug discovery and cell line development. By optimizing multiple drug characteristics simultaneously, this platform accelerates the timeline from concept to clinic while increasing the probability of success in therapeutic development. The company is uniquely positioned to screen billions of cells per week, enabling rapid transformation from AI-designed antibodies to wet lab-validated candidates in as little as six weeks.
Recent achievements include the presentation of positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody program. The company has initiated IND-enabling studies and plans to submit an Investigational New Drug application in the first quarter of 2025. Additionally, Absci has forged strategic partnerships, such as a high-profile collaboration with AstraZeneca aimed at advancing an AI-designed oncology candidate, potentially valued at up to $247 million.
Financially, Absci has strengthened its balance sheet through successful public offerings, raising approximately $86 million in gross proceeds. This financial boost ensures the company has the resources needed to advance its internal programs and continue investment in its groundbreaking platform.
Absci's innovative approach and commitment to leveraging AI for drug discovery have not only enhanced its internal pipeline but also attracted significant industry partnerships. The company’s vision of delivering breakthrough therapeutics at the click of a button continues to drive its mission forward, promising better and faster solutions for patients worldwide.
Absci (Nasdaq: ABSI), a leader in generative AI for drug creation, will release its second-quarter 2024 financial and operating results on August 14, 2024, after market close. The announcement will include business updates and financial performance. A follow-up conference call is scheduled for 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Investors can access the live audio webcast on Absci's investor relations website, with an archived replay available post-event.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, announced on July 1, 2024, the granting of a non-statutory stock option to Ms. Shelby Walker, the new Chief Legal Officer. The option allows her to purchase 613,000 shares of Absci's common stock at an exercise price of $3.01 per share, the closing price on the grant date. This inducement grant, approved under Absci’s 2023 Inducement Plan, aims to attract and retain top talent. The 10-year term stock option vests over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following three years.
Absci (Nasdaq: ABSI) has announced its participation in the Morgan Stanley 3rd Annual Life Sciences AI Summit. The event is scheduled for June 26-27, 2024, in New York, NY. As a data-first generative AI drug creation company, Absci aims to showcase its innovative approaches in the life sciences sector during this prestigious summit. Interested individuals can contact their Morgan Stanley representatives for registration details.
Absci (Nasdaq: ABSI), specializing in generative AI for drug creation, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled for June 10, 2024, at 2:00 p.m. Eastern Time in Miami, FL. Absci management will present at the conference, which will be accessible via live and archived webcast on the company's investor relations website.
Absci (Nasdaq: ABSI) reported its Q1 2024 financial and operational results, highlighting key advancements in its drug creation programs. The company initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody, and progressed ABS-201 and ABS-301 through preclinical stages. Absci completed an $86.4 million public offering in March 2024, enhancing its financial position. Despite a decline in revenue to $0.9 million from $1.3 million year-over-year, net loss decreased from $23.4 million to $22.0 million. R&D expenses lowered to $12.2 million, and SG&A expenses reduced to $8.7 million. Absci's cash, equivalents, and short-term investments stood at $161.5 million as of March 31, 2024, expected to fund operations into H1 2027.
FAQ
What is the current stock price of Absci Corporation (ABSI)?
What is the market cap of Absci Corporation (ABSI)?
What does Absci Corporation specialize in?
What is Absci's Integrated Drug Creation™ platform?
What are some of Absci's recent achievements?
How has Absci strengthened its financial position?
What is the significance of Absci's collaboration with AstraZeneca?
Where are Absci's main operational facilities located?
What is the timeline for ABS-101's clinical trials?
How does Absci's AI technology contribute to drug discovery?
What are some of the internal programs Absci is focusing on?
How can interested parties stay updated on Absci's developments?
